Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 4/20 | 0.38 |
| ▸ | CTSB | P07858 | 4/20 | 0.38 |
| ▸ | CTSH | P09668 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66693 | 0.79 | CTSK (0.43) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL66694 | 0.79 | CTSK (0.43) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL1864365 | 0.78 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL27994060 | 0.78 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL23278923 | 0.77 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL2716403 | 0.77 | CTSK (0.36) | CTSKCTSS | |
| SCHEMBL19400988 | 0.77 | CTSK (0.39) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL25185691 | 0.77 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL30639521 | 0.77 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL23005035 | 0.76 | ATM (0.45) | NPY5RHTR2CSLC6A4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268863-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7947710-B2 | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2195314-B1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2195314-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009029257-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.] OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | THERAVANCE, INC | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062332-A1 | Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | CTSK 4189/4885CTSS 3688/4885CTSL 4484/4885 |
| US-20110144152-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | CTSK 4189/4885CTSS 3688/4885CTSL 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.